Grant: Discovery Grants Program - Individual
Dalhousie University
$24,000.00
Encapsulation for improved manufacturing and controlled-delivery of therapeutic compounds
EF 2010-11
Résumé
In the development of an effective therapeutic product, the synthesis and purification of the drug are only part of the process. It is also important to consider how the drug will be delivered. Liposomes or lipid vesicles are an attractive delivery system for administering functional compounds. Liposomal systems are known to increase drug retention time and to reduce toxic side effects after administration. One area of great interest is the use of liposomes in drug delivery systems administered by inhalation for a targeted, sustained and non-invasive means of delivering drugs to the lungs. The microencapsulation of liposome-entrapped compounds in biodegradable capsules offers a possible means of drug delivery to the lungs with increased stability and drug retention. This research has the potential for treating diseases such as tuberculosis and diabetes more effectively and without painful injections. Such benefits will undoubtedly improve the health and quality of life of the many Canadians who suffer from such diseases.
The goal of this research is to develop a novel processing route incorporating emulsification and spray-drying to produce microencapsulated liposomal drug particles with improved stability and controlled-release properties for inhalation. This will be achieved by first establishing formulation and processing parameters for liposome formation and the entrapment of active compounds. Biodegradable particles would then be produced by emulsification and spray-drying of liposomal solutions. Key factors for assessing suitable manufacturing techniques include: the integrity of the drugs and liposomes after processing, whether the particles have characteristics suitable for inhalation and the rate of particle degradation and drug release.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
341213-2007
Name nom
Brooks, MarianneSuLing
Department département
Process Engineering and Applied Science
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2007
Award amount
24000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
4
Nb partie
4
Application title
Encapsulation for improved manufacturing and controlled-delivery of therapeutic compounds
Keyword
NSERC
Application summary
In the development of an effective therapeutic product, the synthesis and purification of the drug are only part of the process. It is also important to consider how the drug will be delivered. Liposomes or lipid vesicles are an attractive delivery system for administering functional compounds. Liposomal systems are known to increase drug retention time and to reduce toxic side effects after administration. One area of great interest is the use of liposomes in drug delivery systems administered by inhalation for a targeted, sustained and non-invasive means of delivering drugs to the lungs. The microencapsulation of liposome-entrapped compounds in biodegradable capsules offers a possible means of drug delivery to the lungs with increased stability and drug retention. This research has the potential for treating diseases such as tuberculosis and diabetes more effectively and without painful injections. Such benefits will undoubtedly improve the health and quality of life of the many Canadians who suffer from such diseases.
The goal of this research is to develop a novel processing route incorporating emulsification and spray-drying to produce microencapsulated liposomal drug particles with improved stability and controlled-release properties for inhalation. This will be achieved by first establishing formulation and processing parameters for liposome formation and the entrapment of active compounds. Biodegradable particles would then be produced by emulsification and spray-drying of liposomal solutions. Key factors for assessing suitable manufacturing techniques include: the integrity of the drugs and liposomes after processing, whether the particles have characteristics suitable for inhalation and the rate of particle degradation and drug release.